Estrigenix has been awarded phase 1 SBIR grant
We are thrilled to share that Estrigenix Therapeutics has been awarded a phase 1 SBIR grant from the National Institute of Health. The one-year grant provides funds to support pre-clinical studies on one of Estrigenix’s lead compounds to reduce women’s… Read More